Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

Yu-Li Su^1,2, Shih-Yu Huang², Chung-Wen Kuo², Ling-Yi Xiao³, Chang-Ting Lin², Yi-Hua Chen², Li-Chung Chang², Ming-Chun Kuo², Chia-Che Wu², Jei-Ming Peng⁴, Chia-Ling Wu⁵, Hsuan-Ying Huang^6,7, Chih-Yen Chien^8,9

¹Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University College of Medicine, Kaohsiung, Taiwan.

²Division of Hematology Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

³Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.

⁴Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

⁵ACT Genomics Co., Ltd, Taipei, Taiwan cychein3965@adm.cgmh.org.tw a120600310@yahoo.com jalinwu@actgenomics.com.

⁶Department of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan cychein3965@adm.cgmh.org.tw a120600310@yahoo.com jalinwu@actgenomics.com.

⁷College of Medicine, Chang Gung University, Taoyuan, Taiwan.

⁸Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University College of Medicine, Kaohsiung, Taiwan cychein3965@adm.cgmh.org.tw a120600310@yahoo.com jalinwu@actgenomics.com.

⁹Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved overall survival in metastatic urothelial carcinoma (mUC). However, predictive biomarkers for therapeutic response remain insufficiently defined. Although some genomic alterations have been implicated in modulating tumor immunogenicity and ICI sensitivity in other cancers, evidence in mUC remains limited and warrants furth…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.